Global Biomarker Translation Services Market, By Product (Reagents, Instruments), Functional Genomics (Transfection, Real-time PCR, RNA Interference, Mutational Analysis, SNP Analysis, Microarray Analysis), Pathway Analysis (Bead-based Analysis, Microarray Analysis, Proteomics Tools), Biomarker Discovery (Mass Spectrometry, Real-time PCR, Microarray Analysis, Statistical Analysis, Bioinformatics, DNA Sequencing, Others), End Use (Clinical Research, Government and Academic Institutes, Biotechnology and Pharmaceutical Companies, Hospitals and Clinics, and Others) – Industry T
rends and Forecast to 2029
Biomarker Translation Services Market Analysis and Size
Biomarker translation services analyzers have been increasingly popular in recent decades as a result of major technological breakthroughs and expanding healthcare business demands. Biomarker translation services focus on examining internal body fluids and provide precise diagnostic information. Modern biomarker translation services are built on traditional manual laboratory tests. However, as technology has progressed, testing methods have developed, and various tests may now be performed in automated laboratories utilizing complex devices such as chemical analyzers.
Data Bridge Market Research analyses that the biomarker translation services market which was USD 56.81 billion in 2021, would rocket up to USD 130.92 billion by 2029, and is expected to undergo a CAGR of 11.0% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Biomarker Translation Services Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Reagents, Instruments), Functional Genomics (Transfection, Real-time PCR, RNA Interference, Mutational Analysis, SNP Analysis, Microarray Analysis), Pathway Analysis (Bead-based Analysis, Microarray Analysis, Proteomics Tools), Biomarker Discovery (Mass Spectrometry, Real-time PCR, Microarray Analysis, Statistical Analysis, Bioinformatics, DNA Sequencing, Others), End Use (Clinical Research, Government and Academic Institutes, Biotechnology and Pharmaceutical Companies, Hospitals and Clinics, and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), QIAGEN (Germany), PerkinElmer, Inc. (U.S.), Merck KGaA (Germany ), Bio-Rad Laboratories, Inc. (U.S.), Enzo Biochem, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Eurofins Scientific (Luxembourg), Agilent Technologies, Inc. (U.S.), Bruker (U.S.), Siemens (U.S.), Epigenomics AG (Germany), General Electric (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Biomarkers (also known as signature molecule or molecular marker) are basically utilized to check how the body responds to treatment of any condition or disease and assist in examining the organ functions and other health conditions. These play a vital role in the imaging technology so that they can provide clear imaging of oncology tumors and other problems.
Biomarker Translation Services Market Dynamics
Drivers
- Increasing number of patients with rising population
The rising need for non-invasive cancer diagnostics is one of the major factors propelling the biomarkers translation services market forward. Furthermore, the rising number of cancer patients and research programmes, as well as the rise in unhealthy lifestyles and chronic diseases like as diabetes and cardiovascular problems, all contribute to the market's overall growth.
- Increasing number of CROs
The low cost of clinical trials in emerging countries, the increasing prevalence of cancer, and new research initiatives are expected to accelerate the biomarkers market's growth during the forecast period. The use of minimally invasive techniques for the identification of conditions such as cancer, on the other hand, represents an opportunity that will start the germination of the biomarkers translation services market in the forecast period 2022 to 2029.
- Growing importance of companion diagnostics
The biomarkers translation services market is expected to rise due to reasons such as rising cancer prevalence worldwide, increased finances and grants for biomarker research, and continual product improvements.
Opportunities
Biomarker technologies are also being promoted by governments, which are boosting financing for biomarker research. As a result, increased R&D activities will likely boost the biomarker translation services market forward in the coming years. Furthermore, the increasing use of biomarker technologies in drug development and genome mapping studies, as well as a growing inclination for tailored medications, are driving the biomarker translation services market.
Restraints/Challenges
However, obstacles such as high investment requirements, high treatment costs, and expensive capital expenditure on equipment are expected to stymie market expansion, as are technical challenges with sample collection and a lack of suitable reimbursement.
This biomarker translation services market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the biomarker translation services market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Biomarker Translation Services Market
The COVID-19 outbreak caused widespread disruption in nearly every industry. In its realm, the healthcare sector also saw an unparalleled influence. However, this is not the case in the biomarker industry, as biomarkers are critical in the development of chronic-care medicines, where the government and pharmaceutical firms will invest heavily, stifling market growth. Various studies have been undertaken, and biomarkers have been discovered to have an important role in diagnosing and treating COVID-19.
Recent Development
- In February 2022, Abbott Laboratories released Lingo, a consumer bio wearable that can track important body signals and help consumers better understand and improve their overall health. It could allow biohackers to use a continuous stream of data rather than periodic finger-prick tests, urine samples, and breath readings.
- OncoDNA, a genomic and prognostic business, released the OncoDEEP kit in February 2022. The kit provides a complete workflow solution that allows laboratories with NGS capabilities to undertake thorough biomarker testing, perform advanced data analysis, and assist oncologists in providing the most effective and customised cancer treatments for their patients.
Global Biomarker Translation Services Market Scope
The biomarker translation services market is segmented on the basis of products, functional genomics, pathway analysis, biomarker discovery and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Reagents
- Instruments
Functional Genomics
- Transfection
- Real-time PCR
- RNA Interference
- Mutational Analysis
- SNP Analysis
- Microarray Analysis
Pathway Analysis
- Bead-based Analysis
- Microarray Analysis
- Proteomics Tools
Biomarker Discovery
- Mass Spectrometry
- Real-time PCR
- Microarray Analysis
- Statistical Analysis
- Bioinformatics
- DNA Sequencing
- Others
End Use
- Clinical Research
- Government and Academic Institutes
- Biotechnology and Pharmaceutical Companies
- Hospitals and Clinics
- Others
Biomarker Translation Services Market Regional Analysis/Insights
The biomarker translation services market is analysed and market size insights and trends are provided by country, products, functional genomics, pathway analysis, biomarker discovery and end use as referenced above.
The countries covered in the biomarker translation services market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the biomarker translation services market due to the growing number of geriatric population along with adoption of innovative medical technology.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the rising health awareness among the people.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Biomarker Translation Services Market Share Analysis
The biomarker translation services market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to biomarker translation services market.
Some of the major players operating in the biomarker translation services market are:
- F. Hoffmann-La Roche Ltd. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Abbott (U.S.)
- QIAGEN (Germany)
- PerkinElmer, Inc. (U.S.)
- Merck KGaA (Germany)
- Bio-Rad Laboratories, Inc. (U.S.)
- Enzo Biochem, Inc. (U.S.)
- Charles River Laboratories International, Inc. (U.S.)
- Eurofins Scientific (Luxembourg)
- Agilent Technologies, Inc. (U.S.)
- Bruker (U.S.)
- Siemens (U.S.)
- Epigenomics AG (Germany)
- General Electric (U.S.)
SKU-